Navigation Links
Missouri Man Alleges Five Years of Actos Use Caused his Bladder Cancer; Parker Waichman LLP Files Lawsuit on Victim’s Behalf
Date:5/8/2013

New York, NY (PRWEB) May 08, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Missouri man who developed bladder cancer, allegedly from using Actos. The suit was filed on April 2, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0705), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos on or before May 20, 2004 through on or after July 18, 2009, about which time he stopped taking the drug and had developed bladder cancer, allegedly as a result of taking Actos. The Defendants allegedly knew that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. He is seeking damages for permanent injuries, emotional distress, economic loss due to medical expenses and living-related expenses due to a new lifestyle.

Thousands of Actos lawsuits have been filed in state and federal courts across the country, according to an April 16, 2013, Bloomberg report. Actos is a Type 2 diabetes medication that was approved by the U.S. Food and Drug Administration in 1999. In 2011, the agency updated the label to warn that users may face an increased risk of bladder cancer after taking the drug for only one year.

Since then, research has continued to suggest that Actos is associated with bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. Then, the July 3, 2012 Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/Actos_lawsuit_Sailor/05/prweb10715147.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Majority of Missouri tan salons allow pre-teens
2. Hormone Replacement Clinic, Renew Health and Wellness Opens in St. Louis, Missouri Area. New Center Specializes in Anti-Aging Therapies for both Women and Men.
3. InsuranceCalculator.net Now Provides Competitive Car Insurance Quotes To Missouri Drivers
4. Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
5. Wisconsin Woman Alleges She was Injured by Transvaginal Mesh Devices in Lawsuit Filed by Parker Waichman LLP
6. Skechers Lawsuit Filed By Wright & Schulte on Behalf of an Alabama Woman Alleges Serious Ankle Injury Was Caused by The Design of Skechers Shape-Ups
7. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
8. New Lawsuit Alleges Fosamax Increases Risk of Injury: Now, AttorneyOne Can Provide Advice
9. New Lawsuit alleges Actos caused Bladder Cancer
10. New Lawsuit Alleges Teen Molestation by Ex-Deputy
11. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... of SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one ... critical information securely from multiple locations. For the first time, employees can access ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home ... world to manage stress and anxiety. , “Buzzies change the way we interact ... co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint Solution ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National ... sleep is likely not the only cause of the sunken-eye look, which can include ... look older or in poor health are likely due to genetics, dehydration, allergies, and ...
(Date:3/23/2017)... El Segundo, CA (PRWEB) , ... March 23, ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. ... primary source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  Ethicon* today ... Medical, Inc., a privately held medical device company ... System for the surgical treatment of Gastroesophageal Reflux ... strategy of expanding its portfolio of minimally invasive ... medical conditions. Financial terms of the transaction have ...
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 23, 2017  A new genetic test has ... of individuals who carry HLA-B*15:02 and ... yet potentially deadly side effect of certain medications ... gene HLA-B*15:02 is strongly associated with ... syndrome and toxic epidermal necrolysis in patients treated ...
Breaking Medicine Technology: